Related Experiment Video

Updated: Jul 13, 2026

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Interferon and lamivudine monotherapy on chronic hepatitis B in Japan

Fumitaka Suzuki1, Hiromitsu Kumada

  • 1Department of Hepatology, Toranomon Hospital, Tokyo, Japan.

Hepatology Research : the Official Journal of the Japan Society of Hepatology
|July 14, 2007
PubMed

Insights

Interferon therapy shows better response with longer treatment duration for chronic hepatitis B. Lamivudine therapy in some patients led to HBsAg loss, indicating potential for viral clearance.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis B (CHB) affects numerous individuals globally.
  • Interferon (IFN) and lamivudine are established treatments for CHB.
  • Understanding treatment efficacy and resistance patterns is crucial for patient management.

Purpose of the Study:

  • To evaluate the efficacy of interferon monotherapy for chronic hepatitis B in Japan.
  • To assess the long-term outcomes of lamivudine monotherapy in Japanese patients with chronic hepatitis B.
  • To compare short-term versus long-term interferon therapy response rates.

Main Methods:

  • Analysis of data from 66 Japanese patients treated with 6-month interferon therapy.
  • Evaluation of long-term interferon therapy efficacy in 52 e-antigen positive CHB patients.
  • Review of data from 290 CHB patients treated with lamivudine for over 3 years.

Main Results:

  • Six-month interferon therapy yielded a 20% response rate (9/45 patients), with younger patients and higher ALT levels showing better response.
  • Twelve-month interferon therapy improved the response rate to 31% (among 52 patients).
  • Long-term lamivudine therapy showed YMDD motif mutation in 58% (167/290) and breakthrough hepatitis in 32% (93/290) of patients. HBsAg loss occurred in 15 patients.

Conclusions:

  • Long-term interferon therapy demonstrates superior response rates compared to short-term therapy for CHB.
  • Lamivudine therapy can lead to HBsAg loss in a subset of patients, suggesting potential for viral eradication.
  • Further research is needed to optimize treatment strategies and manage drug resistance in CHB.
Abstract

More Related Videos

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons09:11

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...